Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison
DOI:
https://doi.org/10.56782/pps.36Keywords:
atrial fibrillation, apixaban, dabigatran, rivaroxaban, anticoagulantsAbstract
Atrial fibrillation (AF) is a major and widespread health problem. Its main and most threatening complication, ischemic stroke, is responsible for a great number of deaths and disability worldwide. This makes anticoagulation a priority in AF management. Non-vitamin K antagonist oral anticoagulants (NOAC) are currently the most effective and safe option for patients with nonvalvular atrial fibrillation. Rivaroxaban, apixaban, edoxaban and dabigatran are non-inferior to warfarin in terms of stroke and systemic embolism prevention. However, warfarin use is associated with higher rates of major bleedings than any NOAC. Different drugs and mechanism of action among NOACs may result in differences in terms of efficacy and safety between them. This review aims to assess these differences by summarizing data available in online databases and European Society of Cardiology guidelines. There are major studies comparing each of NOACs to warfarin, however there is only limited data comparing apixaban, rivaroxaban and dabigatran directly. Both direct and indirect comparisons suggest that apixaban, rivaroxaban and dabigatran use is associated with similar reduction of stroke and systemic embolism risk. In terms of safety, anticoagulation with apixaban results in lower major bleeding risk relative to dabigatran and rivaroxaban.
Downloads
References
Hindricks, G., et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibril-lation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Asso-ciation (EHRA) of the ESC. Eur Heart J, 2021. 42(5): p. 373-498. DOI: https://doi.org/10.1093/eurheartj/ehaa945
Wan, Y., et al., Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes, 2008. 1(2): p. 84-91. DOI: https://doi.org/10.1161/CIRCOUTCOMES.108.796185
Johnson, J.A. and L.H. Cavallari, Warfarin pharmacogenetics. Trends Cardiovasc Med, 2015. 25(1): p. 33-41. DOI: https://doi.org/10.1016/j.tcm.2014.09.001
EMA. Charakterystyka Produktu Leczniczego Xarelto. Available from: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf.
EMA. Charakterystyka Produktu Leczniczego Eliquis. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf.
EMA. Charakterystyka Produktu Leczniczego Pradaxa. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.
EMA. Charakterystyka Produktu Leczniczego Lixiana. Available from: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf.
Eriksson, B.I., et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med, 2008. 358(26): p. 2765-75. DOI: https://doi.org/10.1056/NEJMoa0800374
Lassen, M.R., et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med, 2008. 358(26): p. 2776-86. DOI: https://doi.org/10.1056/NEJMoa076016
Patel, M.R., et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011. 365(10): p. 883-91. DOI: https://doi.org/10.1056/NEJMoa1009638
Granger, C.B., et al., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011. 365(11): p. 981-92. DOI: https://doi.org/10.1056/NEJMoa1107039
Giugliano, R.P., et al., Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013. 369(22): p. 2093-104. DOI: https://doi.org/10.1056/NEJMoa1310907
Connolly, S.J., et al., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009. 361(12): p. 1139-51. DOI: https://doi.org/10.1056/NEJMoa0905561
Huisman, M.V., et al., The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol, 2017. 69(7): p. 777-785. DOI: https://doi.org/10.1016/j.jacc.2016.11.061
Staerk, L., et al., Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. Sci Rep, 2016. 6: p. 31477. DOI: https://doi.org/10.1038/srep31477
Haas, S., et al., Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J, 2019. 213: p. 35-46. DOI: https://doi.org/10.1016/j.ahj.2019.03.013
Mantha, S. and J. Ansell, An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost, 2012. 108(3): p. 476-84. DOI: https://doi.org/10.1160/TH12-02-0093
Noseworthy, P.A., et al., Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest, 2016. 150(6): p. 1302-1312. DOI: https://doi.org/10.1016/j.chest.2016.07.013
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
